Compare LCNB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | ARMP |
|---|---|---|
| Founded | 1877 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 199.7M |
| IPO Year | 1999 | 1996 |
| Metric | LCNB | ARMP |
|---|---|---|
| Price | $19.47 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 23.0K | ★ 74.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.31 | $2.88 |
| 52 Week High | $21.32 | $14.98 |
| Indicator | LCNB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 54.05 |
| Support Level | $19.01 | $3.98 |
| Resistance Level | $20.48 | $5.63 |
| Average True Range (ATR) | 0.47 | 0.52 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 51.62 | 41.37 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.